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GENETIC DISORDERS – DEVELOPMENT
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Polymorphisms in the nephrin gene and diabetic nephropathy of specific gene loci or susceptibility genes [2]. Most of
in type 1 diabetic patients. the genes investigated so far have been involved in blood
Background. Several mutations in the nephrin gene are re- pressure, cardiovascular disease, glucose metabolism, orsponsible for the lack of slit membrane of the glomeruli leading
glomerular basement membrane. With the discovery ofto massive proteinuria present already in utero. Variations in
nephrin, the glomerular podocyte layer, which is one ofthe nephrin gene may also affect the degree of proteinuria in
acquired kidney diseases. We tested the hypothesis of whether the barriers separating the glomerular capillary from the
any of the polymorphisms identified in the coding region of urinary space, has drawn a great deal of attention. This
the nephrin gene were associated with diabetic nephropathy.
transmembrane protein has been shown to be locatedMethods. In a case-control, cross-sectional study, 996 Finn-
specifically at the slit diaphragm separating the podocyteish type 1 diabetic patients from the FinnDiane Study were
genotyped by standard polymerase chain reaction protocol. foot processes [3].
Results. The frequencies of the rare alleles in the E117K, At least 60 mutations in the nephrin gene (NPHS1)
R408Q, and N1077S polymorphisms in the entire cohort were have been identified [4]. Most of these mutations are34%, 8%, and 12%, respectively. When comparing patients
disease-causing, resulting in the lack of the nephrin pro-with a mutant allele with the wild genotype there was no differ-
tein with consequent congenital nephrosis (CNF), char-ence between the patients with end-stage renal disease, protein-
uria, microalbuminuria, and those with a normal albumin excre- acterized by massive proteinuria already in utero [5].
tion rate (df 3, 2 1.62, 1.31 and 0.77). Neither were the However, several sequence variants were also found in
polymorphisms associated with the progression of kidney dis-
a healthy control population, suggesting that they areease, nor with creatinine clearance and albumin excretion rate.
common polymorphisms. The functional implication ofConclusion. This study does not support an involvement of
the coding region of the nephrin gene in the pathogenesis of these polymorphisms is not known but they might influ-
diabetic nephropathy in type 1 diabetic patients. ence the permeability of the slit diaphragm in other kid-
ney diseases in which proteinuria is displayed [6]. In a
study by Benigni et al [7] blocking both the angiotensin
Diabetic nephropathy, which is characterized by pro- II synthesis by an angiotensin-converting enzyme (ACE)
teinuria, an elevated blood pressure and a relentless de- inhibitor and the activity by an angiotensin II type 2
cline in renal function [1], develops in approximately inhibitor (AT2), a down-regulation of the nephrin gene
25% to 35% of all type 1 diabetic patients. There is was totally prevented in rats with experimental nephro-
evidence for a genetic involvement in the pathogenesis sis. Proteinuria is also a distinct feature of diabetic ne-
of the complication but so far there are only sparse data phropathy and in animal models the expression levels
of nephrin-specific mRNA indicate that nephrin is asso-
ciated with early changes of diabetic nephropathy [8].1 A complete listing of the FinnDiane Study Group can be found in
the Acknowledgments section. Furthermore, the amount of proteinuria is diminished
by ACE inhibitors [9] as well as by AT2 inhibitors [10].Key words: type 1 diabetes, diabetic nephropathy, nephrin, polymor-
phism, slit diaphragm, end stage renal disease, proteinuria. It is interesting that irbesartan, which is an AT2 blocker,
normalized the expression of glomerular nephrin in rats
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Presently, the role of the nephrin gene in the develop- was measured with radioimmunoassay (RIA) (Pharma-
cia, Uppsala, Sweden) and serum C-peptide concentra-ment of diabetes and diabetic nephropathy is not estab-
lished. Therefore, the aim of the study was to elucidate tions with a Human C-peptide RIA kit (Linco Research
Inc., St. Charles, MO, USA). Hemoglobin A1c (HbA1c) waswhether any of the common polymorphisms in the cod-
ing region of the nephrin gene is associated with diabetic measured using standardized assays in each referral cen-
ter (normal range 4.0 to 6.0). Serum high-density lipopro-nephropathy or its progression in type 1 diabetic patients.
tein (HDL)-, low-density lipoprotein (LDL)-, and total
cholesterol and triglycerides were analyzed using routine
METHODS
standardized laboratory methods at each center.
Study group
GenotypingThis study is part of the ongoing Finnish Diabetic
Nephropathy (FinnDiane) Study, a comprehensive, multi- The polymorphisms of the nephrin gene were deter-
mined from DNA samples extracted from peripherallycenter, nationwide project with the aim to phenotype
25% of all adult patients with type 1 diabetes in Finland. drawn blood samples. Genotyping, by an investigator
unaware of the phenotypes, was performed using regularThe first 1006 patients of the FinnDiane cohort with an
ascertained renal status were recruited from 20 referral polymerase chain reaction (PCR) with two previously de-
scribed primer sequences for each polymorphism span-centers between 1994 and 1999. The patients were re-
quired to be C-peptide negative (0.3 nmol/L) and to ning two exons of the gene [6]. One of the primers in each
PCR reaction was biotinylated and the genotypes werehave permanent insulin treatment initiated before the
age of 40 years, within 1 year of the diabetes diagnosis. determined using a solid-phase minisequencing method
[12]. In the E117K polymorphism located on the exon 3,Six patients with residual C-peptide secretion and four
with evidence of nondiabetic kidney disease were ex- a reverse minisequencing primer, 5-CACGAGCTCG
GGCCCCATCT-3, was used, whereas in the R408Q andcluded. The renal status was based on the albumin excre-
tion rate (AER) in at least three consecutive overnight N1077S polymorphisms located on the exon 10 and 24,
forward minisequencing primers, 5-CTGACATTCCTor 24-hour urine collections. The patients with a normal
AER (20 g/minute or 30 mg/24 hours, N  321) GGCGCGG-3 and 5-GGGCTTCTGCTCCTCTCC-3
were used, respectively. Genotyping of the E117K poly-were required to have a diabetes duration 15 years in
order to ensure their renal status. A total of 166 patients morphism failed in 35 patients due to sparse DNA, re-
sulting in spurious results in the minisequencing reactionhad microalbuminuria (AER, 20 to 200 g/minute or 30
to 300 mg/24 hours), 325 had proteinuria (AER 200 (3% of the total study population), whereas in the R408Q
and N1077S polymorphisms, PCR failure occurred in onlyg/minute or 300 mg/24 hours) and 184 had end-stage
renal disease (ESRD). A few patients with earlier mani- one and five patients, respectively. Furthermore, three sug-
gested polymorphisms, the T295I on exon 8, E447K onfested proteinuria (N 15) had a serum creatinine value
130mol/L but no recent urine collection was available exon 11, and R1140C on exon 27, were genotyped ac-
cording to previously designed PCR primers [4, 13] usingand so they were classified as having proteinuria. ESRD
patients were either on dialysis (N 44) or had a kidney forward minisequencing primers of 5-AGCGTGGGG
CACAGAGCACA-3, 5-CCGCCCAGAAACTGTGGtransplant (N  140). The year of renal replacement
therapy initiation and diabetic nephropathy diagnosis ATT-3, and 5-CAGAGGCAGAGCCGTATTAC-3,
respectively.was obtained from medical records. Retinopathy status
was assessed based on indirect ophthalmoscopy or reti-
Statistical analysisnal photography and information about laser treatment,
diabetes diagnosis, antihypertensive medication (AHT), Descriptive data are expressed as mean SEM unless
otherwise stated. Categorical variables were comparedand cardiovascular disease (CVD), which includes coro-
nary heart disease (CHD), acute myocardial infarction using the chi-square test. Normally distributed continu-
ous variables were tested with Student t test, while non-(AMI) and stroke, was also obtained from medical re-
cords. Informed consent was obtained from all subjects normally distributed variables were logarithmically trans-
formed or assessed with the Kruskal-Wallis tests. Allparticipating in the study; the study protocol followed
the principles expressed in the Declaration of Helsinki statistical analyses were also performed separately for
each gender but since there were no differences betweenand was approved by all local ethics committees.
gender, data were pooled. Analyses were carried out using
Assays a STATISTICA 4.1 statistical package (Tulsa, OK, USA).
A P value less than 0.05 was considered statistically sig-Serum and urine creatinine levels for calculation of cre-
atinine clearance were measured at a central laboratory nificant. Linkage disequilibrium (LD) analyses were per-
formed by the programs LinkDos (Laboratoire de Gen-by a modified Jaffe´ reaction (Boehringer Mannheim,
Mannheim, Germany). Urinary albumin concentration etique et Environment, Montpellier, France) and Genepop
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Table 1. Clinical characteristics of 996 type 1 diabetic patients included in the study
Normoalbuminuria Microalbuminuria Proteinuria End-stage renal disease
N  321 N  166 N  325 N  184
Male/female % 41/59 64/36 59/41 59/41
Age years 40.40.5 38.10.9 40.30.5 44.00.6
Duration of diabetes years 26.70.4 25.10.7 28.00.4 32.00.6
Body mass index kg/m 2 24.90.2 25.70.3 25.90.2 23.80.3
Waist-to-hip ratio
Male 0.900.01 0.910.01 0.940.01 0.950.01
Female 0.810.01 0.820.01 0.830.01 0.870.01
Antihypertensive therapy % 47 (15) 99 (62) 304 (96) 154 (91)
Cardiovascular disease % 10 (3) 6 (4) 42 (13) 48 (27)
Acute myocardial infarction % 5 (2) 4 (2) 21 (7) 23 (13)
Coronary heart disease % 9 (3) 6 (4) 33 (11) 37 (21)
Stroke % 2 (1) 0 (0) 17 (5) 18 (10)
Retinal laser treatment % 92 (29) 84 (51) 260 (81) 179 (99)
Systolic blood pressure mm Hg 1321 1381 1441 1542
Diastolic blood pressure mm Hg 791 821 831 871
Hemoglobin A1c % 8.00.1 8.70.1 8.90.1 8.40.1
Albumin excretion rate lg/mina 5 (1–17) 38 (3–198) — —
(mg/24 hours)a — — 1063 (10–16600) —
Serum creatinine lmol/L 83 (56–129) 90 (62–128) 131 (60–1278) 150 (59–1176)
Creatinine clearance mL/s1/1.73 m2 1.620.02 1.510.04 1.020.04 0.810.07
Serum total cholesterol mmol/L 4.90.1 4.90.1 5.10.1 5.60.1
Serum HDL cholesterol mmol/L 1.70.1 1.50.1 1.40.1 1.50.1
Serum LDL cholesterol mmol/L 2.80.1 2.80.1 3.40.1 3.30.1
Serum triglycerides mmol/L
Male 1.10.1 1.30.1 1.80.1 1.70.1
Female 0.90.1 1.20.1 1.40.1 1.60.1
Abbreviations are: HDL cholesterol, high-density lipoprotein cholesterol; LDL, low-density lipoprotein. Data are meansSEM, median (range) or N (%).
a Some patients with previously abnormal albumin excretion ratio (AER) had responded to antihypertensive treatment and showed a regression of AER at the
time of investigation
Table 2. Distribution of genotypes and rare allele frequencies of(version 1.2; Laboratoire de Genetique et Environment,
the RAGE polymorphisms
Montpellier, France). The distribution of the genotype
Polymorphism NORMO MICRO PROT ESRD P valuecombinations was tested by the program MENDEL [14].
E117K NS
EE 146 (46) 73 (44) 140 (44) 65 (40)
EK 132 (41) 75 (46) 134 (43) 68 (42)RESULTS
KK 40 (13) 17 (10) 41 (13) 30 (18)
The patients were divided into four groups based on K 0.33 0.33 0.34 0.39 NS
R408Q NStheir renal status. The clinical characteristics of the four
RR 273 (85) 140 (84) 267 (82) 156 (85)patient groups are shown in Table 1. RQ 45 (14) 26 (16) 58 (18) 24 (13)
The frequencies of the mutant alleles in the E117K, QQ 3 (1) 0 (0) 0 (0) 3 (2)
Q 0.08 0.08 0.09 0.08 NSR408Q, and N1077S polymorphisms, located on exon 3,
N1077S NS10, and 24, were 34%, 8%, and 12% in the entire cohort, NN 242 (76) 128 (77) 253 (78) 145 (78)
respectively. All four groups in the three polymorphisms NS 74 (23) 32 (19) 67 (21) 38 (21)
SS 3 (1) 6 (4) 3 (1) 1 (1)were in Hardy-Weinberg equilibrium except for the pa-
S 0.13 0.13 0.11 0.11 NStients with microalbuminuria in the N1077S polymor-
Abbreviations are: NS, non significant; NORMO, normal albumin excretionphism, where a slight deviation was observed (2 4.34). rate; MICRO, microalbuminuria; PROT, proteinuria; ESRD, end-stage renal
disease. Data are N (%).No differences in the genotypes or allele frequencies
were observed between any of the four groups when
they all were analyzed together or when the genotypes
or allele frequencies were analyzed separately between genotype among the 82 first patients genotyped and,
each group (Table 2). Cohorts were sufficiently large to consequently, no further genotyping was performed.
yield 80% power to detect a 9% deviation of mutant There was no difference in time from onset of diabetes
genotype frequency with P 0.05 and had 99.5% power to the diagnosis of nephropathy or initiation of renal
to detect a 14% deviation. All three polymorphisms were replacement therapy in the patients with the wild geno-
in tight LD with each other (P  0.0001). Regarding the type in comparison to patients with one or two mutant
proposed T295I, E447K, and R1140C polymorphisms on alleles of each polymorphism (Table 3). Furthermore,
AER and creatinine clearance in patients with micro-exon 8, 11, and 27, there were none with the variant
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Table 3. Clinical parameters by nephrin genotypes At present, there are no known specific genetic defects
that increase the risk for diabetic nephropathy, althoughPolymorphism Wild genotype Mutation P value
there is evidence for a genetic component in the patho-Time from onset of diabetes mellitus to nephropathy years
E117K 19.0 19.3 NS genesis of diabetic nephropathy. We used several ap-
R408Q 19.2 19.0 NS proaches in order to detect possible associations between
N1077S 19.0 20.0 NS
all the amino acid changing polymorphisms of the nephrinTime from onset of diabetes mellitus to ESRD years
E117K 26.1 25.8 NS gene and diabetic nephropathy. However, we did not ob-
R408Q 26.0 26.6 NS serve any differences in the genotype frequencies between
N1077S 25.8 27.5 NS
the groups divided based on the AER. Neither wereAge at onset of diabetes
E117K 12.1 13.2 0.03 there any differences in the AER, creatinine clearance,
R408Q 12.7 13.0 NS or time of onset of diabetes to the diagnosis of diabetic
N1077S 12.9 12.4 NS
nephropathy and/or ESRD based on the genotypes.Albumin excretion ratio (mg/24 hours)a
E117K 665 832 NS The study population consisted of 996 carefully pheno-
R408Q 725 916 NS typed subjects and the control group with normal AER
N1077S 882 655 NS
had a long duration of diabetes to ensure affection status.Creatinine clearance (mL/s1/1.73 m2)a
E117K 1.23 1.15 NS Given the population size we should have had the statisti-
R408Q 1.18 1.24 NS cal power needed to detect a potential difference in geno-
N1077S 1.19 1.19 NS
type frequencies. Population bias is also unlikely, since
ESRD is end-stage renal disease. the patients were recruited from 20 different referral cen-a Only patients with microalbuminuria and proteinuria included
ters treating type 1 diabetic patients regardless of compli-
cation status, and the patients were recruited for this study
in a consecutive order in order to avoid selection bias.
albuminuria or proteinuria did not differ between pa- All the 29 exons and the immediate promoter region
tients with the wild genotype compared to one or two of the nephrin gene have been sequenced and screened
mutant alleles (Table 3). Interestingly, patients with the for mutations in non-Finnish control individuals [4].
K genotype of the E117K polymorphism had a later age Three suggested polymorphisms were found previously
at onset of diabetes compared to patients with the wild [6] of which the N1077S polymorphism was present only
genotype (Table 3). in one control individual. Each of the polymorphisms in
Haplotype analysis is a powerful method in analyses that study was also found in those with manifest CNF
of close-by single nucleotide polymorphisms (SNPs). and they were located in both the immunoglobulin motif
Due to the structure of the study, we do not know the and the transmembrane domain of the nephrin polypep-
phase of the chromosomes analyzed. Recently, it has been tide chain. Our study shows that the variants are indeed
common polymorphisms present both in diabetic pa-suggested [15] that information from as few as two or
tients with and without nephropathy. It is not knownthree SNPs can identify a haplotype block [16] in a chro-
whether these polymorphisms affect the function of themosomal region. We analyzed whether specific combina-
domains in the nephrin protein, since they were all pres-tions of the three genotypes would associate with pro-
ent in those with CNF as well. However, all the polymor-teinuria, ESRD and the dichotomal variables comprising
phisms analyzed in this study changed the amino acid,CVD or AHT, thus revealing a chromosomal strand har-
although the hydrophobicity was of the same magnitude.boring the actual predisposing variant (data not shown).
A disturbance of the nephrin protein could occur in aNo genotype combination associated with ESRD, pro-
diabetic milieu, explaining why the previously studiedteinuria, or AHT, but the combination E117E, R408Q,
nondiabetic control group was phenotypically healthy.and N1077N genotypes were more prevalent in ESRD
Such a view is, however, not supported by our study,individuals with CHD cases than the in the ones without
since there were no differences in the studied renal vari-(P  0.04). However, the finding is only marginally sig-
ables AER or creatinine clearance or time from onsetnificant and obviously suffers from multiple testing; hence,
of diabetes mellitus to overt nephropathy and/or ESRD.it needs to be confirmed by an independent study.
No variant genotypes were found in the only suggested
polymorphism with a significant change on charge selec-
DISCUSSION tivity (T295I). None of the polymorphisms with an amino
In this study we found no support for an involvement acid change occurred in the fibronectin or intracellular
of the polymorphisms in the coding region of the nephrin domain of the nephrin protein. In the intracellular do-
gene in the pathogenesis of diabetic nephropathy in type main one sequence variant with an unknown phenotype
1 diabetic patients. Patients with the mutant allele of the effect was found (R1140C) [4], but no variant allele was
E117K polymorphism had, however, a later onset of present in our patients.
Several recent expression studies exhibit a link be-diabetes than those with wild genotype.
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participating in the collection of the patients: A. Halonen, A. Koistinen,
(RAS). According to recent experimental data, a block- P. Koskiaho, M. Laukkanen, J. Saltevo, M. Tiihonen (Central Finland
ade of the AT2 and ACE have resulted in a change Central Hospital); A.-C. Blomqvist, M. Forsen, H. Granlund, B. Nyroos
(Central Hospital of Aland Islands); P. Kinnunen, A. Orvola, T. Salo-in the nephrin expression in severe nephrosis [10] and
nen, A. Va¨ha¨nen (Central Hospital of Kanta-Hame); R. Paldanius, M.diabetes [11, 17]. This could possibly reflect an additional Riihela¨, L. Ryysy (Central Hospital of Kymenlaakso); P. Nyla¨nden, A.
renoprotective mechanism for these drugs. We cannot Sademies (Central Hospital of Lansi-Pohja); S. Anderson, B. Asplund,
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Ha¨ma¨la¨inen, H. Virtamo, M. Va¨ha¨talo (City of Turku Health Centre);affect nephrin expression in our patients and thereby S. Jokelainen, P. Kemppainen, A.-M. Mankinen, M. Sankari (Kainuu
have an impact on the AER. Therefore, we also per- Central Hospital); L. Hyva¨rinen, S. Severinkangas, T. Tulokas (Lapland
Central Hospital); A. Gynther, R. Manninen, P. Nironen, M. Salminen,formed the analyses separately in the patients with and
T. Va¨nttinen (Mikkeli Central Hospital); U.-M. Henttula, A. Rissanen,without drugs blocking the RAS but still no differences H. Turtola, M. Voutilainen (North Karelian Hospital); H. Haapama¨ki,
could be observed in the genotypes between the four A. Helantera¨, H. Miettinen (Paijat-Hame Central Hospital); M. Juhola,
P. Kunelius, M.-L. Lahdenma¨ki, P. Pa¨a¨kko¨nen, M. Rautavirta (Sata-groups (data not shown).
kunta Central Hospital); T. Pulli, P. Sallinen, H. Valtonen, A. VartiaThe weak association between the E117K polymor-
(Savonlinna Central Hospital); E. Korpi-Hyo¨va¨lti, T. Latvala, E. Leijala
phism and the onset time of diabetes cannot be explained (Seinajoki Central Hospital); T. Hotti, R. Ha¨rko¨nen, U. Nyholm, R.
Vanamo† (South Karelia Hospital District); I. Ala-Houhala, T. Kunin-at this point. It could, indeed, be due to multiple compari-
gas, P. Lampinen, M. Ma¨a¨tta¨, H. Oksala, T. Oksanen, K. Salonen, H.son, although a recent study by Palme´n et al [18] interest-
Tauriainen, S. Tulokas (Tampere University Hospital); I. Ha¨ma¨la¨inen,
ingly showed that nephrin, which was initially thought H. Virtamo, M. Va¨ha¨talo (Turku Health Center); M. Asola, K. Brei-
tholz, R. Eskola, K. Metsa¨rinne, U. Pietila¨, P. Saarinen, R. Tuominen,to be specific for kidney glomerular podocytes, is also
S. A¨yra¨pa¨a¨ (Turku University Central Hospital); and S. Bergkulla, U.expressed in the pancreatic beta cells although its specific
Hautama¨ki, V.-A. Myllyniemi, I. Rusk (Vasa Central Hospital).
function is still unknown. We can, thus, not rule out the
possibility that any variation in the expression of the Reprint requests to: Per-Henrik Groop, Folkhalsan Research Center,
Biomedicum Helsinki, Haartmaninkatu 8 (C318b), POB 63, FIN-00014,nephrin gene in pancreas affects the beta cell function
University of Helsinki, Finland.possibly affecting the onset age of diabetes. E-mail: per-henrik.groop@folkhalsan.fi
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